In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles

International Journal of Antimicrobial Agents

Volumn 22, Issue 1, 2003, Pages 14-27

  Livermore, D M ^a   Mushtaq, S ^a   James, D ^a   Potz, N ^a   Walker, R A ^b   Charlett, A ^c   Warburton, F ^c   Johnson, A P ^a   Warner, M ^a   Henwood, C J ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^b Wells Healthcare Communications Ltd   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Broad spectrum antibiotics; Piperacillin tazobactam; Resistance surveillance

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; DALFOPRISTIN PLUS QUINUPRISTIN; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HEALTH SURVEY; HOSPITALIZATION; HUMAN; IRELAND; NONHUMAN; PATIENT; PREVALENCE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; STANDARDIZATION; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; UNITED KINGDOM;

EID: 0037899246     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00108-0     Document Type: Article

References (21)

1. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 113:1998;412-420.
2. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 118:2000;146-155.
3. Mosdell D.M., Morris D.M., Voltura A., et al. Antibiotic treatment for surgical peritonitis. Ann. Surg. 214:1991;543-549.
4. Chen H.Y., Bonfiglio G., Allen M., et al. Multicentre survey of the comparative in vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. J. Antimicrob. Chemother. 32:1993;247-266.
5. Reacher M.H., Shah A., Livermore D.M., et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ. 320:2000;213-216.
6. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:2002;634-640.
7. French G.L., Shannon K.P., Simmons N. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and β-lactam-β-lactamase inhibitor combinations by hyperproduction of SHV-5 β-lactamase. J. Clin. Microbiol. 34:1996;358-363.
8. Andrews J.M. SAC working party on susceptibility testing. BSAC standardized disc susceptibility testing method. J. Antimicrob. Chemother. 48:(Suppl. A):2001;43-57.
9. Dutka-Malen S., Evers S., Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:1995;1434.
10. Henwood C.J., Livermore D.M., Johnson A.P., et al. Susceptibility of Gram-positive cocci in 25 UK hospitals to linezolid and other antimicrobial agents. J. Antimicrob. Chemother. 46:2000;931-940.
11. Henwood C.J., Livermore D.M., James D., Warner M. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J. Antimicrob. Chemother. 47:2001;789-799.
12. Hawkey P.M., Birkenhead D., Kerr K.G., Newton K.E., Hyde W.A. Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions. J. Antimicrob. Chemother. 31:1993;47-55.
13. Bonfiglio G., Livermore D.M. Effect of media composition on the susceptibility of Xanthomonas maltophilia to β-lactam antibiotics. J. Antimicrob. Chemother. 28:1991;837-842.
14. Johnson A.P., Aucken H., Cavendish S., et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J. Antimicrob. Chemother. 48:2001;144.
15. Livermore D.M., Winstanley T.G., Shannon K.P. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J. Antimicrob. Chemother. 48:(Suppl. 1):2001;87-102.
16. Gheorghiu R., Yuan M., Hall L.M.C., Livermore D.M. Bases of variation in resistance to β-lactams in Klebsiella oxytoca isolates hyperproducing K1 β-lactamase. J. Antimicrob. Chemother. 40:1997;533-541.
17. MacGowan A.P., Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48:(Suppl. 1):2001;17-28.
18. Livermore D.M. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:1995;557-584.
19. Rice L.B., Carias L.L., Bonomo R.A., Shlaes D.M. Molecular genetics of resistance to both ceftazidime and β-lactam-β-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to β-lactam therapy. J. Infect. Dis. 173:1996;151-158.
20. Seetulsingh P.S., Hall L.M., Livermore D.M. Activity of clavulanate combinations against TEM-1 β-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. J. Antimicrob. Chemother. 27:1991;749-759.
21. Rice L.B., Carias L.L., Hujer A.M., et al. High-level expression of chromosomally encoded SHV-1 β-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:2000;362-367.